Commentary: Dosage–Response in the Treatment of Gaucher Disease by Enzyme Replacement Therapy
- 31 August 2000
- journal article
- editorial
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 26 (4) , 303-306
- https://doi.org/10.1006/bcmd.2000.0311
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Comparative Efficacy of Dose Regimens in Enzyme Replacement Therapy of Type I Gaucher DiseaseBlood Cells, Molecules, and Diseases, 2000
- 8 Enzyme replacement therapy for Gaucher's diseaseBailliere's Clinical Haematology, 1997
- The Clinical Course of Treated and Untreated Gaucher Disease. A Study of 45 PatientsBlood Cells, Molecules, and Diseases, 1995
- Replacement therapy with imiglucerase for type 1 Gaucher's diseaseThe Lancet, 1995
- Individualised low-dose alglucerase therapy for type 1 Gaucher's diseaseThe Lancet, 1995
- Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 monthsBlood, 1993
- Treatment of Gaucher's DiseaseNew England Journal of Medicine, 1993
- A Less Costly Regimen of Alglucerase to Treat Gaucher's DiseaseNew England Journal of Medicine, 1992
- Enzyme Augmentation in Moderate to Life-Threatening Gaucher DiseasePediatric Research, 1992
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991